This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Acadia (ACHC) in Your Portfolio
by Zacks Equity Research
Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth.
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Adobe's (ADBE) first-quarter fiscal 2023 results are expected to reflect gains from solid momentum across the Digital Media and Digital Experience segments.
Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JD.com (JD) to Release Q4 Earnings: What's in the Offing?
by Zacks Equity Research
JD.com's (JD) fourth-quarter results are likely to reflect strength across JD Retail and JD Logistics amid uncertainties related to the coronavirus pandemic.
Docebo (DCBO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Docebo's (DCBO) fourth-quarter performance is expected to have gained from steady demand for its enterprise learnings solutions boosted by an expanding client base.
MongoDB (MDB) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
MongoDB's (MDB) fourth-quarter fiscal 2023 results are expected to reflect the high retention rate and growth in direct sales customers.
Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
by Zacks Equity Research
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.
Zacks.com featured highlights Lamb Weston, Catalyst Pharmaceuticals and Northeast Community Bank
by Zacks Equity Research
Lamb Weston, Catalyst Pharmaceuticals and Northeast Community Bank have been highlighted in this Screen of The Week article.
Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings
by Zacks Equity Research
Hewlett Packard's (HPE) fiscal first-quarter results are likely to reflect gains from growing demand for its cloud services amid the ongoing digital transformation trend.
3 Top Profitable Stocks to Buy on Solid Net Income Ratio
by Tirthankar Chakraborty
Lamb Weston (LW), Catalyst Pharmaceuticals (CPRX) and Northeast Community Bancorp (NECB) are some of the top picks with a high net income ratio.
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.38, moving +0.79% from the previous trading session.
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Factors to Note Ahead of Zscaler's (ZS) Q2 Earnings Release
by Zacks Equity Research
The increased demand for security and networking products amid the ongoing hybrid work environment and digitization process is likely to have aided Zscaler's (ZS) second-quarter performance.
Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
Catalyst Pharmaceutical (CPRX) Stock Moves -1.74%: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.25, moving -1.74% from the previous trading session.
Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.
Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.